Kitov Pharma Ltd. (KTOV)
Stock Price:
$0.752 USD
-0.028 (-3.59%)
Updated Aug 12, 2020 12:30 PM EDT - Market open
Key Info
| Market Cap |
129.42M |
| Revenue (ttm) |
1,000,000 |
| Net Income (ttm) |
-5.89M |
| Shares Out |
162.87M |
| EPS (ttm) |
-0.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$0.752 |
| Previous Close |
$0.780 |
| Change ($) |
-0.028 |
| Change (%) |
-3.59% |
| Day's Open |
0.790 |
| Day's Range |
0.750 - 0.793 |
| Day's Volume |
5,181,641 |
| 52-Week Range |
0.220 - 1.440 |
More Stats
| Market Cap |
129.42M |
| Enterprise Value |
123.25M |
| Earnings Date (est) |
Feb 11, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
162.87M |
| Float |
33.47M |
| EPS (basic) |
-0.3 |
| EPS (diluted) |
-0.30 |
| FCF / Share |
-0.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.52M |
| Short Ratio |
0.24 |
| Short % of Float |
n/a |
| Beta |
2.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
129.42 |
| PB Ratio |
14.03 |
| Revenue |
1,000,000 |
| Operating Income |
-7.16M |
| Net Income |
-5.89M |
| Free Cash Flow |
-5.59M |
| Net Cash |
6.17M |
| Net Cash / Share |
0.04 |
| Gross Margin |
100.00% |
| Operating Margin |
-715.60% |
| Profit Margin |
-589.30% |
| FCF Margin |
-559.20% |
| ROA |
-28.87% |
| ROE |
-53.91% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: $0.752
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 1.00 | 1.00 | 0.10 | - | - | - | - |
| Revenue Growth | 0% | 900% | - | - | - | - | - |
| Gross Profit | 1.00 | 1.00 | 0.10 | - | - | - | - |
| Operating Income | -7.16 | -7.83 | -11.97 | -7.18 | -4.07 | -4.46 | -2.55 |
| Net Income | -5.89 | -5.57 | -12.91 | -12.13 | -4.20 | -5.25 | -2.63 |
| Shares Outstanding | 19.37 | 14.21 | 9.46 | 5.76 | 0.96 | 0.22 | 0.08 |
| Earnings Per Share | -0.30 | -0.39 | -1.37 | -2.11 | -4.40 | -23.40 | -32.00 |
| Operating Cash Flow | -5.58 | -8.48 | -8.63 | -6.26 | -3.31 | -4.53 | -0.51 |
| Capital Expenditures | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | - | - |
| Free Cash Flow | -5.59 | -8.50 | -8.64 | -6.27 | -3.32 | -4.53 | -0.51 |
| Cash & Equivalents | 6.40 | 6.68 | 7.44 | 14.66 | 10.56 | 1.31 | 0.00 |
| Total Debt | 0.22 | 0.55 | 2.01 | - | 0.14 | 0.37 | - |
| Net Cash / Debt | 6.17 | 6.13 | 5.42 | 14.66 | 10.42 | 0.94 | 0.00 |
| Assets | 14.72 | 14.72 | 14.18 | 14.91 | 10.81 | 1.76 | - |
| Liabilities | 3.86 | 3.72 | 5.50 | 1.53 | 1.38 | 0.99 | - |
| Book Value | 10.42 | 10.52 | 7.41 | 13.39 | 9.43 | 0.77 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kitov Pharma Ltd. |
| Country |
Israel |
| Employees |
9 |
| CEO |
Isaac Israel |
Stock Information
| Ticker Symbol |
KTOV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KTOV |
Description
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd is headquartered in Tel Aviv, Israel.